Showing 1 - 20 results of 32 for search 'Megan Othus', query time: 0.06s
Refine Results
-
1
-
2
-
3
-
4
-
5
Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia by Daisuke Araki, Megan Othus, Roland B. Walter, Vicky Sandhu, Brenda M. Sandmaier, Pamela S. Becker, Frederick R. Appelbaum, Elihu H. Estey
Published 2015-07-01
Article -
6
Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data by Megan Othus, Guillermo Garcia-Manero, John E. Godwin, James K. Weick, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey
Published 2022-07-01
Article -
7
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. by Shailender Bhatia, James Moon, Kim A Margolin, Jeffrey S Weber, Christopher D Lao, Megan Othus, Ana M Aparicio, Antoni Ribas, Vernon K Sondak
Published 2012-01-01
Article -
8
Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML by Mohamed L. Sorror, Shirali Agarwal, Megan Othus, Ylinne Lynch, Jennifer E. Nyland, Mary‐Elizabeth Percival, Pamela S. Becker, Frederick R. Appelbaum, Elihu H. Estey
Published 2020-09-01
Article -
9
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute... by Corentin Orvain, Jacob A. Wilson, Min Fang, Brenda M. Sandmaier, Eduardo Rodríguez-Arbolí, Brent L. Wood, Megan Othus, Frederick R. Appelbaum, Roland B. Walter
Published 2022-08-01
Article -
10
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI by Megan Othus, Wim van Putten, Bob Lowenberg, Stephen H. Petersdorf, Sucha Nand, Harry Erba, Frederick Appelbaum, Robert Hills, Nigel Russell, Alan Burnett, Elihu Estey
Published 2016-07-01
Article -
11
Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML by Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter
Published 2025-02-01
Article -
12
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia by Raffaele Palmieri, Megan Othus, Guang-Shing Cheng, Francesco Buccisano, Giovangiacinto Paterno, Luca Maurillo, Maria Ilaria Del Principe, Giuseppe Sconocchia, Adriano Venditti, Roland B. Walter
Published 2022-08-01
Article -
13
Time independent factors that predict relapse in adults with acute myeloid leukemia by John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Paul Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Published 2024-01-01
Article -
14
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG by Roland B. Walter, Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey
Published 2015-10-01
Article -
15
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility by Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey
Published 2020-07-01
Article -
16
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell tra... by Eduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, Lucas C. Zarling, Brenda M. Sandmaier, Filippo Milano, Gary Schoch, Chris Davis, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter
Published 2022-09-01
Article -
17
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort by Howard Streicher, Elad Sharon, Razelle Kurzrock, Young Kwang Chae, Benjamin Tan, Megan Othus, Christine McLeod, Charles Blanke, Helen X Chen, Sandip P Patel, Gabby Lopez, Tridu Huynh, Timothy Kuzel, Christopher W Ryan
Published 2024-07-01
Article -
18
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia by Laura W. Dillon, Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H. Smith, Elizabeth Schmidt, Charles C. Valentine III, Jesse J. Salk, Brent L Wood, Harry P. Erba, Jerald P. Radich, Christopher S. Hourigan
Published 2023-08-01
Article -
19
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm by Roland B. Walter, Megan Othus, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bruno C. Medeiros, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey
Published 2018-03-01
Article -
20
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis by Sarah A. Buckley, Brent L. Wood, Megan Othus, Christopher S. Hourigan, Celalettin Ustun, Michael A. Linden, Todd E. DeFor, Michele Malagola, Chloe Anthias, Veronika Valkova, Christopher G. Kanakry, Bernd Gruhn, Francesco Buccisano, Beth Devine, Roland B. Walter
Published 2017-05-01
Article